A phase I trial evaluated the B7-H3 inhibitor enoblituzumab combined with the anti-PD-1 inhibitor retifanlimab across multiple tumor types, showing an ORR of 33.3% in 18 HNSCC patients, including five partial responses (PRs) and one complete response (CR)[133]. Here, CD276 is linked to neoplasm.